113. Role of CD46 on Ad35 Vector-Mediated Transduction

Although successful in many rodent models of malignant gliomas, results of clinical adenoviral gene therapy trials using replication deficient vectors have been disappointing. One of the explanations of the discrepancy between results in animal models and clinical trials is the low expression of the Coxsackie Adenovirus receptor (CAR), the main high affinity receptor for binding of adenovirus serotype 5, on primary glioma cells as opposed to established glioma cell lines. To obtain improved adenoviral vectors, we made use of the differential tropism of the naturally occurring 51 human adenoviral serotypes to test the hypothesis that adenoviral vectors, binding to other receptors than CAR, would result in improved infection of primary glioma cells.